Patents by Inventor Antonio Scardino

Antonio Scardino has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7976843
    Abstract: Identifying subdominant/cryptic epitopes (I) that are presented by a HLA (human leukocyte antigen) Class I molecule, is new. Identifying subdominant/cryptic epitopes (I) that are presented by a HLA (human leukocyte antigen) Class I molecule comprising selecting at least one peptide (II) of 8-11 amino acids (aa), potentially representing an epitope for Class I presentation, from a protein against which a cytotoxic T cell (CTL) response is to be raised. (II) corresponds to a non-immunogenic peptide with low affinity for Class I molecules. Variants (IIa) of (II) are prepared in which the N-terminal aa is replaced by Tyr and their immunogenicity detected by identifying those that generate a CTL response against target cells expressing the parent protein. Peptide sequences from which active (IIa) are derived are then identified.
    Type: Grant
    Filed: August 6, 2008
    Date of Patent: July 12, 2011
    Assignees: Institut National de la Santa et de la Recherche Medicale (Inserm), Institut Gustave Roussy (IGR)
    Inventors: Kostas Kosmatopoulos, Sophie Tourdot, Antonio Scardino, David Alexandre Gross
  • Publication number: 20090269363
    Abstract: Identifying subdominant/cryptic epitopes (I) that are presented by a HLA (human leukocyte antigen) Class I molecule, is new. Identifying subdominant/cryptic epitopes (I) that are presented by a HLA (human leukocyte antigen) Class I molecule comprising selecting at least one peptide (II) of 8-11 amino acids (aa), potentially representing an epitope for Class I presentation, from a protein against which a cytotoxic T cell (CTL) response is to be raised. (II) corresponds to a non-immunogenic peptide with low affinity for Class I molecules. Variants (IIa) of (II) are prepared in which the N-terminal aa is replaced by Tyr and their immunogenicity detected by identifying those that generate a CTL response against target cells expressing the parent protein. Peptide sequences from which active (IIa) are derived are then identified.
    Type: Application
    Filed: August 6, 2008
    Publication date: October 29, 2009
    Inventors: Kostas Kosmatopoulos, Sophie Tourdot, Antonio Scardino, David Alexandre Gross
  • Patent number: 7425606
    Abstract: Identifying subdominant/cryptic epitopes (I) that are presented by a HLA (human leukocyte antigen) Class I molecule, is new. Identifying subdominant/cryptic epitopes (I) that are presented by a HLA (human leukocyte antigen) Class I molecule comprising selecting at least one peptide (II) of 8-11 amino acids (aa), potentially representing an epitope for Class I presentation, from a protein against which a cytotoxic T cell (CTL) response is to be raised. (II) corresponds to a non-immunogenic peptide with low affinity for Class I molecules. Variants (IIa) of (II) are prepared in which the N-terminal aa is replaced by Tyr and their immunogenicity detected by identifying those that generate a CTL response against target cells expressing the parent protein. Peptide sequences from which active (IIa) are derived are then identified.
    Type: Grant
    Filed: July 20, 2001
    Date of Patent: September 16, 2008
    Assignees: Institut National de la Sante et de la Recherche Medicale (Inserm), Institut Gustave Roussy (IGR)
    Inventors: Kostas Kosmatopoulos, Sophie Tourdot, Antonio Scardino, Alexandre David Gross
  • Publication number: 20040072240
    Abstract: The invention concerns a method for identifying sub-dominant/cryptic epitopes exhibited by a class I HLA molecule, said method comprising at least the following steps: a) selecting, from the sequence of a protein with respect to which it is desired to induce a cytotoxic T lymphocyte response, at least a peptide sequence of 8 to 11 amino acids capable of constituting an epitope of said protein exhibited by a class I HLA molecule, and corresponding to a peptide with low affinity for said class I HLA molecule and non-immunogenic; b) preparing, for each selected sequence, a variant peptide derived from said sequence, by substituting the N-terminal amino acid with a tyrosine residue; c) determining the immunogenicity of each variant peptide obtained at step b) by selecting, among the latter, each immunogenic peptide, generating a CTL response specific to the target cells expressing the protein wherefrom it is derived and identifying the peptide sequence wherefrom said immunogenic peptide is derived.
    Type: Application
    Filed: October 2, 2003
    Publication date: April 15, 2004
    Inventors: Kostas Kosmatopoulos, Sophie Tourdot, Antonio Scardino, David Alexander Gross